Clinical Trials - Patient

Clinical Trials - Patient

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Randomized Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer with HER2 Amplification (S1613) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP vs R-CHOP in Treatment-Naive Subjects with High Risk Diffuse Large B-Cell Lymphoma Who Possess the Genomic Biomarker DGM1 (ENGINE Study) (Pharmatech DLBC-JIT) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial Comparing Adjuvant Pembrolizumab vs Standard of Care Observation in Completely Resected Merkel Cell Carcinoma of Skin (EA6174) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201) (Cypress2) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel vs Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers (S1815) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Paclitaxel and Carboplatin vs Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-naive Sex Cord Stromal Tumors of the Ovary (GOG0264) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Pelvic Radiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic Only Recurrence of Carcinoma of the Uterine Corpus (GOG-0238)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (CT4006) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Phase III Study of Pembrolizumab vs Placebo in Combination with NeoAdjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High Risk Early Stage Hormone Positive, HER2 Negative Breast Cancer (MK3475-756) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Placebo Controlled Pilot Study of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced NonSmall Cell Lung Cancer (A221504)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Study of Cabozantinib vs Placebo in Patients with Advanced Neuroendocrine or Carcinoid Tumors after Progression on Everolimus (A021602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double-Blind, Placebo Controlled Study of Pazopanib with or without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (XYN-602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Multicenter Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (17058) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (INTR@PID) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Sequential 2 Arm Open Label Study to Evaluate teh Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Sequential 2 Arm Open Label Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study Comparing Venetoclax + Fulvestrant vs Fulvestrant In Women with Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (pembrolizumab) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy (S1607) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of MGCD516 in Patients with Advanced Solid Tumors (17038) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Nivolumab in Combination with either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration- Resistant Metastatic Prostate Cancer (17149) II
Mary Beth WIlwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Pembrolizumab and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (GY016) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Poziotinib in Patients wit Non Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon20 Insertion Mutation (17143) (SPI-POZ-202) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members